nach oben

06.05.2024 | Research

Risk factors and survival outcomes in children with early cardiotoxicity after allogeneic hematopoietic stem cell transplantation

verfasst von: Ke Tong, Yan Meng, Luying Zhang, Xiaoying Lei, Qihui Liu, Xianmin Guan, Jie Yu, Ying Dou

Einloggen, um Zugang zu erhalten

Abstract

Cardiotoxicity in children is a potentially fatal complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT); therefore, early identification of risk factors can improve patient prognosis. However, there are few data on the clinical characteristics of early-stage cardiotoxicity in children after allo-HSCT. We conducted a retrospective single-center study of pediatric patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) between January 2016 and December 2022 at the Children's Hospital Affiliated with Chongqing Medical University to evaluate the clinical characteristics of early cardiac events (ECEs) after allo-HSCT and their impact on survival outcomes. We enrolled 444 patients who underwent allo-HSCT—304 males (68%) and 140 females (32%)—with a median age of 3.3 years (1.8–6.5 years) at transplantation. We found that 73 patients (16.4%) had ECEs after allo-HSCT. The ECEs included valvular disease (n = 46), pericardial effusion (n = 38), arrhythmia (n = 9), heart failure (n = 16), and dilated cardiomyopathy (n = 1). Female sex, age ≥ 6 years, body mass index (BMI) < 16 kg/m² and HLA-type mismatches were risk factors for ECEs. We designed a stratified cardiac risk score that included these risk factors, and the higher the score was, the greater the cumulative incidence of ECEs. The occurrence of an ECE was closely associated with a lower overall survival (OS) rate and greater nonrelapse mortality (NRM). In addition, stratified analysis based on the number of combined ECEs showed that the greater the number of combined ECEs was, the more significant the negative impact on OS rates.

Balassa K, Danby R, Rocha V (2019) Haematopoietic stem cell transplants: principles and indications. Br J Hosp Med (Lond) 80(1):33–39. https://doi.org/10.12968/hmed.2019.80.1.33CrossRefPubMed

Barriga F, Ramírez P, Wietstruck A, Rojas N (2012) Hematopoietic stem cell transplantation: clinical use and perspectives. Biol Res 45(3):307–316. https://doi.org/10.4067/S0716-97602012000300012CrossRefPubMed

Zhao Y, He R, Oerther S, Zhou W, Vosough M, Hassan M (2022) Cardiovascular complications in hematopoietic stem cell transplanted patients. J Pers Med 12(11):1797. https://doi.org/10.3390/jpm12111797CrossRefPubMedPubMedCentral

Bhatia S (2011) Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up. Expert Rev Hematol 4(4):437–454. https://doi.org/10.1586/ehm.11.39CrossRefPubMedPubMedCentral

Ohmoto A, Fuji S (2021) Cardiac complications associated with hematopoietic stem-cell transplantation. Bone Marrow Transplant 56(11):2637–2643. https://doi.org/10.1038/s41409-021-01427-2CrossRefPubMed

Buja LM, Ferrans VJ, Graw RG Jr (1976) Cardiac pathologic findings in patients treated with bone marrow transplantation. Hum Pathol 7(1):17–45. https://doi.org/10.1016/s0046-8177(76)80004-4CrossRefPubMed

Rotz SJ, Ryan TD, Jodele S, Jefferies JL, Lane A, Pate A, Hirsch R, Hlavaty J, Levesque AE, Taylor MD, Cash M, Myers KC, El-Bietar JA, Davies SM, Dandoy CE (2017) The injured heart: early cardiac effects of hematopoietic stem cell transplantation in children and young adults. Bone Marrow Transplant 52(8):1171–1179. https://doi.org/10.1038/bmt.2017.62CrossRefPubMed

Rotz SJ, Ryan TD, Hayek SS (2021) Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation. J Thromb Thrombolysis 51(4):854–869. https://doi.org/10.1007/s11239-020-02344-9CrossRefPubMed

Duléry R, Mohty R, Labopin M, Sestili S, Malard F, Brissot E, Battipaglia G, Médiavilla C, Banet A, Van de Wyngaert Z, Paviglianiti A, Belhocine R, Isnard F, Lapusan S, Adaeva R, Vekhoff A, Ledraa T, Legrand O, Cohen A, Bonnin A, Ederhy S, Mohty M (2021) Early Cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation. JACC CardioOncol 3(2):250–259. https://doi.org/10.1016/j.jaccao.2021.02.011CrossRefPubMedPubMedCentral

10.

Yeh J, Whited L, Saliba RM, Rondon G, Banchs J, Shpall E, Champlin R, Popat U (2021) Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era. Blood Adv 5(24):5599–5607. https://doi.org/10.1182/bloodadvances.2021004846CrossRefPubMedPubMedCentral

11.

Duncan CN, Brazauskas R, Huang J, Shaw BE, Majhail NS, Savani BN, Flowers MED, Battiwalla M, Beebe K, Dietz AC, Dvorak CC, Giller R, Jacobsohn DA, Kletzel M, Martin PL, Nemecek ER, Nuechterlein B, Talano JA, Pulsipher MA, Baker KS (2018) Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 53(10):1278–1287. https://doi.org/10.1038/s41409-018-0155-zCrossRefPubMedPubMedCentral

12.

Johansson T, Partanen J, Saavalainen P (2022) HLA allele-specific expression: methods, disease associations, and relevance in hematopoietic stem cell transplantation. Front Immunol 13:1007425. https://doi.org/10.3389/fimmu.2022.1007425CrossRefPubMedPubMedCentral

13.

US Department of Health and Human Services. Common Terminology Criteria for Adverse Events, Version 4.0 (version 4.03) (2009). Available at: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf/. Accessed 28 Nov 2020

14.

Hertenstein B, Stefanic M, Schmeiser T, Scholz M, Göller V, Clausen M, Bunjes D, Wiesneth M, Novotny J, Kochs M (1994) Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant. J Clin Oncol 12(5):998–1004. https://doi.org/10.1200/JCO.1994.12.5.998CrossRefPubMed

15.

Pérez-Valencia AI, Cascos E, Carbonell-Ordeig S, Charry P, Gómez-Hernando M, Rodríguez-Lobato LG, Suárez-Lledó M, Martínez-Cibrian N, Antelo MG, Solano MT, Arcarons J, Nomdedeu M, Cid J, Lozano M, Díaz-Ricart M, Rosiñol L, Esteve J, Urbano-Ispizua Á, Carreras E, Martínez C, Fernández-Avilés F, Rovira M, Salas MQ (2023) Incidence, risk factors, and impact of early cardiac toxicity after allogeneic hematopoietic cell transplant. Blood Adv 7(10):2018–2031. https://doi.org/10.1182/bloodadvances.2022008792CrossRefPubMed

16.

Alblooshi R, Kanfar S, Lord B, Atenafu EG, Michelis FV, Pasic I, Gerbitz A, Al-Shaibani Z, Viswabandya A, Kim DDH, Lam W, Law A, Mattsson J, Kumar R, Lipton JH (2021) Clinical prevalence and outcome of cardiovascular events in the first 100 days postallogeneic hematopoietic stem cell transplant. Eur J Haematol 106(1):32–39. https://doi.org/10.1111/ejh.13482CrossRefPubMed

17.

Armenian SH, Yang D, Teh JB, Atencio LC, Gonzales A, Wong FL, Leisenring WM, Forman SJ, Nakamura R, Chow EJ (2018) Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. Blood Adv 2(14):1756–1764. https://doi.org/10.1182/bloodadvances.2018019117CrossRefPubMedPubMedCentral

18.

Leger KJ, Baker KS, Cushing-Haugen KL, Flowers MED, Leisenring WM, Martin PJ, Mendoza JA, Reding KW, Syrjala KL, Lee SJ, Chow EJ (2018) Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer 124(7):1507–1515. https://doi.org/10.1002/cncr.31227CrossRefPubMed

19.

Tichelli A, Bucher C, Rovó A, Stussi G, Stern M, Paulussen M, Halter J, Meyer-Monard S, Heim D, Tsakiris DA, Biedermann B, Passweg JR, Gratwohl A (2007) Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood 110(9):3463–3471. https://doi.org/10.1182/blood-2006-10-054080CrossRefPubMed

20.

Uderzo C, Pillon M, Corti P, Tridello G, Tana F, Zintl F, Nysom K, Galambrun C, Fagioli F, Varotto S, Messina C, Verdeguer A, Urban C, Faraci M, Dini G, Fedeli S, Tichelli A, Rovelli A, Socié G (2007) Impact of cumulative anthracycline dose, preparative regimen and chronic graft-versus-host disease on pulmonary and cardiac function in children 5 years after allogeneic hematopoietic stem cell transplantation: a prospective evaluation on behalf of the EBMT Pediatric Diseases and Late Effects Working Parties. Bone Marrow Transplant 39(11):667–675. https://doi.org/10.1038/sj.bmt.1705652CrossRefPubMed

21.

Kurauchi K, Nishikawa T, Miyahara E, Okamoto Y, Kawano Y (2017) Role of metabolites of cyclophosphamide in cardiotoxicity. BMC Res Notes 10(1):406. https://doi.org/10.1186/s13104-017-2726-2CrossRefPubMedPubMedCentral

22.

Tong K, Meng Y, Zhang L, Lei X, Guan X, Xiao L, Yu J, Dou Y (2023) Retrospective study of risk factors for pericardial effusion after haematopoietic stem cell transplantation in children. Hematology 28(1):2245259. https://doi.org/10.1080/16078454.2023.2245259CrossRefPubMed

23.

Anasetti C (2008) What are the most important donor and recipient factors affecting the outcome of related and unrelated allogeneic transplantation? Best Pract Res Clin Haematol 21(4):691–697. https://doi.org/10.1016/j.beha.2008.10.002CrossRefPubMedPubMedCentral

24.

Tinianow A, Gay JC, Bearl DW, Connelly JA, Godown J, Kitko CL (2020) Pericardial effusion following hematopoietic stem cell transplantation in children: Incidence, risk factors, and outcomes. Pediatr Transplant 24(5):e13748. https://doi.org/10.1111/petr.13748CrossRefPubMed

25.

Neier M, Jin Z, Kleinman C, Baldinger L, Bhatia M, Silver E, van de Ven C, Morris E, Satwani P, George D, Garvin J, Bradley MB, Schwartz J, Cairo MS (2011) Pericardial effusion post-SCT in pediatric recipients with signs and/or symptoms of cardiac disease. Bone Marrow Transplant 46(4):529–538. https://doi.org/10.1038/bmt.2010.149CrossRefPubMed

26.

Sommer A, Twig G (2018) The impact of childhood and adolescent obesity on cardiovascular risk in adulthood: a systematic review. Curr Diab Rep 18(10):91. https://doi.org/10.1007/s11892-018-1062-9CrossRefPubMed

27.

Freedman DS, Mei Z, Srinivasan SR, Berenson GS, Dietz WH (2007) Cardiovascular risk factors and excess adiposity among overweight children and adolescents: the Bogalusa Heart Study. J Pediatr 150(1):12-17.e2. https://doi.org/10.1016/j.jpeds.2006.08.042CrossRefPubMed

28.

Aldoss O, Gruenstein DH, Bass JL, Steinberger J, Zhang Y, Defor TE, Tolar J, Verneris MR, Orchard PJ (2013) Pericardial effusion after pediatric hematopoietic cell transplant. Pediatr Transplant 17(3):294–299. https://doi.org/10.1111/petr.12062CrossRefPubMed

29.

Yanagisawa R, Ishii E, Motoki N, Yamazaki S, Morita D, Sakashita K, Shiohara M, Tanaka M, Hidaka Y, Kubota N, Hidaka E, Ogiso Y, Nakamura T, Yasukochi S (2015) Pretransplant-corrected QT dispersion as a predictor of pericardial effusion after pediatric hematopoietic stem cell transplantation. Transpl Int 28(5):565–574. https://doi.org/10.1111/tri.12532CrossRefPubMed

30.

Liu YC, Gau JP, Hong YC, Yu YB, Hsiao LT, Liu JH, Chiou TJ, Chen PM, Tzeng CH (2012) Large pericardial effusion as a life-threatening complication after hematopoietic stem cell transplantation-association with chronic GVHD in late-onset adult patients. Ann Hematol 91(12):1953–1958. https://doi.org/10.1007/s00277-012-1541-zCrossRefPubMed

31.

Tonorezos ES, Stillwell EE, Calloway JJ, Glew T, Wessler JD, Rebolledo BJ, Pham A, Steingart RM, Lazarus H, Gale RP, Jakubowski AA, Schaffer WL (2015) Arrhythmias in the setting of hematopoietic cell transplants. Bone Marrow Transplant 50(9):1212–1216. https://doi.org/10.1038/bmt.2015.127CrossRefPubMedPubMedCentral

32.

Lin CJ, Vader JM, Slade M, DiPersio JF, Westervelt P, Romee R (2017) Cardiomyopathy in patients after posttransplant cyclophosphamide-based hematopoietic cell transplantation. Cancer 123(10):1800–1809. https://doi.org/10.1002/cncr.30534CrossRefPubMed

33.

Moriyama S, Fukata M, Hieda M, Yokoyama T, Yoshimoto G, Kusaba H, Nakashima Y, Miyamoto T, Maruyama T, Akashi K (2022) Early-onset cardiac dysfunction following allogeneic haematopoietic stem cell transplantation. Open Heart 9(1):e002007. https://doi.org/10.1136/openhrt-2022-002007CrossRefPubMedPubMedCentral

34.

Dandoy CE, Jodele S, Paff Z, Hirsch R, Ryan TD, Jefferies JL, Cash M, Rotz S, Pate A, Taylor MD, El-Bietar J, Myers KC, Wallace G, Nelson A, Grimley M, Pfeiffer T, Lane A, Davies SM, Chima RS (2017) Team-based approach to identify cardiac toxicity in critically ill hematopoietic stem cell transplant recipients. Pediatr Blood Cancer 64(10). https://doi.org/10.1002/pbc.26513

35.

Diamond M, Ruiz-Mesa C, Corrales-Medina FF, Tamariz LJ, Ziga E, Swaminathan S (2018) Incidence and outcome of pericardial effusion in pediatric patients after hematopoietic stem cell transplant: a single-institution experience. J Pediatr Hematol Oncol 40(2):132–136. https://doi.org/10.1097/MPH.0000000000000974CrossRefPubMed

36.

Jaing TH, Chen SH, Wen YC, Chang TY, Tsai DY, Chung HT, Tsay PK (2017) Factors affecting survival in children with pericardial effusion after hematopoietic stem cell transplantation. Cell Transplant 26(11):1792–1797. https://doi.org/10.1177/0963689717727285CrossRefPubMed

37.

Umeda K, Imai K, Yanagimachi M, Yabe H, Kobayashi M, Takahashi Y, Kajiwara M, Yoshida N, Cho Y, Inoue M, Hashii Y, Atsuta Y, Morio T, Inherited Disease Working Group of the Japan Society for Hematopoietic Cell Transplantation (2020) Impact of graft-versus-host disease on the clinical outcome of allogeneic hematopoietic stem cell transplantation for non-malignant diseases. Int J Hematol 111(6):869–876. https://doi.org/10.1007/s12185-020-02839-4CrossRefPubMed

38.

Ruggeri A, Sun Y, Labopin M, Bacigalupo A, Lorentino F, Arcese W, Santarone S, Gülbas Z, Blaise D, Messina G, Ghavamzadeh A, Malard F, Bruno B, Diez-Martin JL, Koc Y, Ciceri F, Mohty M, Nagler A (2017) Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant. Haematologica 102(2):401–410. https://doi.org/10.3324/haematol.2016.151779CrossRefPubMedPubMedCentral

39.

Soltermann Y, Heim D, Medinger M, Baldomero H, Halter JP, Gerull S, Arranto C, Passweg JR, Kleber M (2019) Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study. Ann Hematol 98(6):1485–1493. https://doi.org/10.1007/s00277-019-03673-3CrossRefPubMed

40.

Zu Y, Zhou J, Fu Y, Fang B, Liu X, Zhang Y, Yu F, Zuo W, Zhou H, Gui R, Li Z, Liu Y, Zhao H, Zhang C, Song Y (2021) Feasibility of reduced-dose posttransplant cyclophosphamide and cotransplantation of peripheral blood stem cells and umbilical cord-derived mesenchymal stem cells for SAA. Sci Rep 11(1):253. https://doi.org/10.1038/s41598-020-80531-7CrossRefPubMedPubMedCentral

Titel: Risk factors and survival outcomes in children with early cardiotoxicity after allogeneic hematopoietic stem cell transplantation
verfasst von: Ke Tong
Yan Meng
Luying Zhang
Xiaoying Lei
Qihui Liu
Xianmin Guan
Jie Yu
Ying Dou
Publikationsdatum: 06.05.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-024-05787-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen